Levin Capital Strategies L.P. Has $179,000 Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Levin Capital Strategies L.P. decreased its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 55.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,000 shares of the company’s stock after selling 24,000 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Eyepoint Pharmaceuticals were worth $179,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $27,000 after purchasing an additional 2,733 shares during the last quarter. R Squared Ltd purchased a new position in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $100,000. Janney Montgomery Scott LLC bought a new stake in Eyepoint Pharmaceuticals during the second quarter worth $114,000. Arizona State Retirement System raised its position in Eyepoint Pharmaceuticals by 12.7% in the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company’s stock valued at $90,000 after buying an additional 1,877 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Eyepoint Pharmaceuticals by 208.8% during the 1st quarter. New York State Common Retirement Fund now owns 20,114 shares of the company’s stock valued at $109,000 after acquiring an additional 13,600 shares in the last quarter. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $12.45 on Tuesday. The company has a market capitalization of $858.14 million, a P/E ratio of -4.65 and a beta of 1.95. The company’s 50-day moving average is $12.85 and its 200 day moving average is $10.16. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $14.91.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, research analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EYPT has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th. Mizuho set a $28.00 price target on shares of Eyepoint Pharmaceuticals in a report on Monday, October 20th. HC Wainwright upped their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.67.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.